MVC’s Measures to Combat COVID-19
As COVID-19 pandemic continues to spread around the world, MVC is proud to be amongst the forerunners that answer the call to develop a vaccine against this global crisis.
In collaboration with the US NIH/NIAID and their solid technology based on culmination of over 15 years of research on coronavirus, MVC develops SARS-CoV-2 vaccine with genetically modified Spike protein as antigen, making it more stable and highly immunogenic.
MVC is conducting animal studies and strives to enter human clinical trials in full speed.
What is Spike Protein
Spike proteins complex is consisted of trimers on the viron surface, forming crown-like shape where the virus gets its name “corona”. Spike protein is the primary surface protein SARS-CoV-2 virus uses to enter and infect human cells, making spike protein highly immunogenic and the target antigen of many vaccine development
Features of MVC’s COVID-19 vaccine:
- Antigen : Highly immunogenic version of the virus protein licensed from the US NIH/NIAID
- Adjuvant : Novel adjuvant skewed toward Th1 immune response
- Production：Highly efficient scale-up production to meet EUA demands